5-Amino-1MQResearch, Evidence & Safety Profile

5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that has attracted growing research interest as a metabolic target. It is sometimes discussed in peptide and biohacking communities alongside true peptides such as MOTS-c, BPC-157, or Epithalon, but chemically it is not a peptide — it is a quinoline-based small organic molecule. Calling it a peptide is a common error in non-scientific sources.

NNMT methylates nicotinamide, converting it to 1-methylnicotinamide (MNA) and consuming a methyl group from S-adenosylmethionine in the process. Because nicotinamide is a precursor to NAD+ (nicotinamide adenine dinucleotide) — a coenzyme central to cellular energy metabolism — high NNMT activity has been proposed to deplete NAD+ availability and shift cellular methyl-group balance. NNMT is overexpressed in white adipose tissue from obese individuals and in some cancer cells, which has driven interest in NNMT inhibition as a potential metabolic and oncologic target.

5-Amino-1MQ was identified in published medicinal-chemistry work on small-molecule NNMT inhibitors. In preclinical models — most prominently in mice fed a high-fat diet — NNMT inhibition with 5-Amino-1MQ has been associated with improvements in body weight, adipose tissue metabolism, and certain markers of metabolic health. None of these findings has been replicated in published controlled human trials.

Evidence and regulatory caution: Published human clinical trial data for 5-Amino-1MQ as a therapeutic intervention has not been identified as of May 2026. The bulk of the literature consists of cell-culture experiments, rodent studies, and medicinal-chemistry characterization of the molecule. Any discussion of effects in humans is therefore extrapolation from preclinical data and should be treated with significant caution. 5-Amino-1MQ has no FDA-approved indication, no established human dose, and no characterized human safety profile.

5-Amino-1MQ acts as a small-molecule inhibitor of NNMT. Its proposed mechanism of action chains together several steps of cellular metabolism:

• NNMT enzymology: NNMT catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). The reaction consumes both a substrate (nicotinamide) and a methyl group (from SAM). 5-Amino-1MQ binds to NNMT and inhibits this reaction.
• NAD+ precursor preservation: Nicotinamide is one of the salvage-pathway precursors for NAD+ biosynthesis. When NNMT is highly active, it diverts nicotinamide toward MNA production rather than allowing it to be salvaged back into the NAD+ pool. Inhibiting NNMT is proposed to preserve nicotinamide for NAD+ regeneration, supporting cellular NAD+ availability — particularly in tissues with high NNMT activity such as adipose tissue in obesity.
• Methyl-group balance: NNMT activity consumes SAM and produces SAH, shifting the SAM/SAH ratio that influences methylation reactions throughout the cell, including DNA and histone methylation. Inhibiting NNMT is proposed to preserve SAM availability for other methyltransferase reactions, which has been hypothesized to affect epigenetic regulation. The downstream consequences of this shift in vivo are not fully characterized.
• Adipocyte metabolism (preclinical): In cell-culture and mouse studies, NNMT inhibition has been associated with increased energy expenditure, altered lipogenesis, and changes in white adipose tissue characteristics. The Kraus et al. 2014 paper in Nature was foundational in establishing NNMT overexpression as a feature of obese white adipose tissue and in proposing NNMT as a metabolic target.
• 1-Methylnicotinamide (MNA) effects: MNA itself is biologically active — it has been described in some studies as a metabolic signaling molecule and stable end-product. The metabolic effects of NNMT inhibition therefore reflect both increased nicotinamide/NAD+ availability and decreased MNA production; separating these is methodologically challenging.

Whether the metabolic effects observed in preclinical NNMT inhibition studies translate to humans at safely achievable plasma concentrations is unknown. NNMT is expressed in multiple tissues, and the consequences of broad NNMT inhibition in a complete organism over time have not been characterized in humans.

The following observations are drawn from preclinical (cell-culture and animal) research. They are not claims of efficacy in humans, and they should not be interpreted as therapeutic benefits. Evidence Level D: minimal-to-no published human evidence, limited preclinical evidence concentrated in a small number of research groups.

• Reduced weight gain in diet-induced obese mice (preclinical): Mice fed a high-fat diet and treated with 5-Amino-1MQ in published studies have shown reduced weight gain compared to vehicle-treated controls. The effect size and durability vary across studies, and no equivalent finding has been published from a controlled human trial.
• Adipose tissue changes (preclinical): NNMT inhibition in mouse models has been associated with changes in white adipose tissue including reduced adipocyte size and altered gene expression patterns. The biological significance and translation to humans is unclear.
• NAD+ pool effects (preclinical): NNMT inhibition has been associated in some cell-culture and tissue studies with preserved or increased NAD+ availability, consistent with the proposed mechanism. The clinical significance of this in humans, where NAD+ regulation involves multiple pathways and tissues, is not established.
• Polypharmacology questions (preclinical): Some 5-Amino-1MQ studies have raised the possibility of effects beyond pure NNMT inhibition — for example, effects on neighboring enzymes or off-target pathways. This is a normal feature of early-stage small-molecule pharmacology and an active area of medicinal chemistry refinement.

Findings observed in mice cannot be assumed to occur in humans. Human metabolic physiology differs substantially from rodent models, particularly with respect to adipose tissue biology, energy expenditure regulation, and the role of NAD+ across tissues. The translation of NNMT inhibition findings from mice to humans is an open scientific question.

The human safety profile of 5-Amino-1MQ has not been characterized. There are no published Phase 1 trials, no FDA-reviewed safety database, and no peer-reviewed reports of human adverse-event monitoring at the population level. The following are considerations that should inform caution, not a complete safety profile.

• No human safety data: The absence of published clinical safety data means dose-limiting toxicities, organ-specific risks, drug-drug interactions, and idiosyncratic adverse events have not been systematically identified in humans. This is the single most important consideration.
• Off-target effects unknown in humans: Small molecules of this class typically have off-target binding to other methyltransferases or unrelated enzymes. The clinical significance in humans is unknown but is the kind of risk Phase 1 trials are designed to identify.
• Tissue-distribution and accumulation: 5-Amino-1MQ is a quaternary ammonium-bearing molecule (the methylated quinolinium nitrogen), which affects its tissue distribution and clearance. Long-term accumulation or specific organ deposition in humans is not characterized.
• Theoretical concerns from NNMT biology: NNMT is expressed in multiple tissues and has roles beyond adipose tissue, including in cancer biology (NNMT is overexpressed in several cancer types but its functional role varies). Sustained systemic NNMT inhibition could have downstream effects on methylation balance and energy metabolism that are not characterized in humans.
• Product-quality risk: Any 5-Amino-1MQ obtained outside of a controlled research setting carries significant uncertainty about purity, identity, residual synthesis impurities, contamination, and dosing accuracy. Research-chemical-channel products are not regulated as pharmaceutical-grade material.
• Not for therapeutic use: 5-Amino-1MQ is a research compound. It has not been evaluated for therapeutic use in any human condition and should not be used to treat, manage, or prevent any disease.

Disclaimer: 5-Amino-1MQ has no FDA-approved dose. No clinical trial has validated a dose, dosing schedule, or route of administration for any human health indication. The following describes doses used in animal research, provided strictly for educational context. It is not a recommendation and should not be interpreted as a guide to human use.

Published preclinical research has used doses in mice generally in the range of 5–20 mg/kg per day, administered orally in drinking water or by gavage in some studies. Translating these doses to humans requires significant extrapolation and is not supported by human pharmacokinetic or pharmacodynamic data. Mouse-to-human dose conversion factors are imprecise, particularly for novel compounds without absorption, distribution, metabolism, and excretion (ADME) characterization in humans.

Doses circulating in DIY research-chemical communities vary widely and are entirely anecdotal. None has been clinically validated. They should not be interpreted as safe or effective doses for any individual.

Because 5-Amino-1MQ has not undergone formal human pharmacokinetic study, the relationship between an oral dose, plasma concentration, tissue exposure, and NNMT inhibition in humans is unknown.

Published research on 5-Amino-1MQ specifically, and on NNMT inhibition more broadly, has expanded since the mid-2010s but remains overwhelmingly preclinical.

• NNMT as a metabolic target: Foundational work by Kraus and colleagues (Nature, 2014) characterized NNMT overexpression in white adipose tissue from obese individuals and used NNMT knockdown in mice to demonstrate metabolic effects, establishing NNMT as a potential metabolic target. This paper is widely cited as the rationale for subsequent NNMT inhibitor development.
• Small-molecule NNMT inhibitor development: Medicinal-chemistry work — including that by Neelakantan and colleagues in the late 2010s — characterized 5-Amino-1MQ and related quinolinium-based inhibitors as nicotinamide-mimetic NNMT inhibitors. These papers established structure-activity relationships and provided early in vitro pharmacology.
• Diet-induced obesity mouse studies: Several published mouse studies have reported metabolic effects of 5-Amino-1MQ in diet-induced obesity models, including changes in body weight, adipose-tissue characteristics, and gene expression. These studies have been carried out by a relatively small number of research groups and have not been independently replicated across multiple labs in the way that more established metabolic targets have.
• Cancer biology research: Separate from the metabolic line of investigation, NNMT inhibition is being explored in oncology research, given NNMT overexpression in several cancer types. This is a distinct research thread with its own preclinical literature.
• Absence of published human trials: As of May 2026, no published Phase 1 or Phase 2 human clinical trial results for 5-Amino-1MQ as a therapeutic intervention have been identified. The compound has not progressed publicly through the conventional clinical development pipeline for any indication.

Evidence classification: Level D — minimal-to-no published human interventional evidence, limited and not-broadly-replicated preclinical evidence. NNMT as a target has stronger underlying biology than the body of work on 5-Amino-1MQ specifically.

5-Amino-1MQ is in an earlier stage of regulatory and clinical research than the better-known compounded peptides. Understanding its status requires separating a few different regulatory questions.

• Not FDA-approved: 5-Amino-1MQ has no FDA approval for any human indication. It has no pending New Drug Application that has been publicly disclosed and no published Phase 1 clinical trial results.
• Not a peptide for compounding purposes: 5-Amino-1MQ is a small organic molecule, not a peptide. The FDA's compounding rules and the Pharmacy Compounding Advisory Committee's reviews of peptides under USP Chapter 797 and related frameworks do not apply to it in the same way they apply to BPC-157, MOTS-c, or similar peptide compounds. It is not on a current FDA Category 1 compoundable list.
• Outside the 2026-02-27 reclassification announcement: Secretary Robert F. Kennedy Jr.'s February 27, 2026 announcement of intent to reclassify approximately 14 peptides addressed peptide compounds. 5-Amino-1MQ is not a peptide, was not among those substances, and is not affected by that pending reclassification process.
• Sold as a research chemical: In the United States, 5-Amino-1MQ is generally sold through research-chemical channels with labeling that designates it for laboratory or research use only — not for human consumption. This labeling distinction is important. Research-chemical-channel products are not pharmaceutical-grade and are not regulated as drugs.
• International variability: Regulatory status outside the United States varies. Some jurisdictions classify quaternary ammonium small molecules under specific controlled-substance or medicinal-product frameworks; others do not. Verify status in your specific jurisdiction.
• Research use: Use of 5-Amino-1MQ in academic and institutional research is governed by standard institutional research protocols (IACUC for animal research, IRB for any human research), but no IRB-approved human protocol with this compound has been publicly reported.